Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial.

Finkelstein JS, Klibanski A, Arnold AL, Toth TL, Hornstein MD, Neer RM

JAMA1 Sept 1998Cited by 91 (Europe PMC)

PMID9757854DOI10.1001/jama.280.12.1067PepBankPUB-09757854

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, added hPTH prevented femoral neck bone loss during nafarelin therapy.
In plain wordsIn women with endometriosis, added hPTH prevented femoral neck bone loss compared with nafarelin alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck bone loss prevention
Study
n = 43
Comparator
Nafarelin alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
BMD change from baseline
4.7%
Femoral neck, nafarelin alone (comparator arm), lower than baseline at 12 months
Source sentences
Summary
In contrast, coadministration of hPTH-(1-34) increased BMD of the anterior-posterior spine by 2.1% (1.1%) (P=.09) and lateral spine by 7.5% (1.9%) (P=.002) and prevented bone loss from the femoral neck, trochanter, and total body, despite severe estrogen deficiency.
5 context sentences(design, population, supporting numbers)
Summary · context
In the women who received nafarelin alone, the mean (SEM) BMDs of the anterior-posterior spine, lateral spine, femoral neck, trochanter, and total body were 4.9% (0.6%) (P<.001), 4.9% (0.8%) (P<.001), 4.7% (1.1%) (P<.001), 4.3% (0.9%) (P<.001), and 2.0% (0.6%) (P= .003) lower than at baseline after…
Summary · context
Randomized controlled trial.
Summary · context
Nafarelin alone (200 microg intranasally twice daily) or nafarelin plus human parathyroid hormone-(1-34) (hPTH-[1-34]) (40 microg subcutaneously daily).
Summary · context
The primary end points were bone mineral density (BMD) of the anterior-posterior and lateral spine, femoral neck, trochanter, radial shaft, and total body at 12 months of treatment.
Summary · context
Forty-three women between the ages of 21 and 45 years with symptomatic endometriosis.
Report a problemFND-0975785403
02HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, added hPTH prevented trochanter bone loss during nafarelin therapy.
In plain wordsIn women with endometriosis, added hPTH prevented trochanter bone loss compared with nafarelin alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrochanter bone loss prevention
Study
n = 43
Comparator
Nafarelin alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
BMD change from baseline
4.3%
Trochanter, nafarelin alone (comparator arm), lower than baseline at 12 months
Source sentences
Summary
In contrast, coadministration of hPTH-(1-34) increased BMD of the anterior-posterior spine by 2.1% (1.1%) (P=.09) and lateral spine by 7.5% (1.9%) (P=.002) and prevented bone loss from the femoral neck, trochanter, and total body, despite severe estrogen deficiency.
5 context sentences(design, population, supporting numbers)
Summary · context
In the women who received nafarelin alone, the mean (SEM) BMDs of the anterior-posterior spine, lateral spine, femoral neck, trochanter, and total body were 4.9% (0.6%) (P<.001), 4.9% (0.8%) (P<.001), 4.7% (1.1%) (P<.001), 4.3% (0.9%) (P<.001), and 2.0% (0.6%) (P= .003) lower than at baseline after…
Summary · context
Randomized controlled trial.
Summary · context
Nafarelin alone (200 microg intranasally twice daily) or nafarelin plus human parathyroid hormone-(1-34) (hPTH-[1-34]) (40 microg subcutaneously daily).
Summary · context
The primary end points were bone mineral density (BMD) of the anterior-posterior and lateral spine, femoral neck, trochanter, radial shaft, and total body at 12 months of treatment.
Summary · context
Forty-three women between the ages of 21 and 45 years with symptomatic endometriosis.
Report a problemFND-0975785404
03HumanRandomized controlled trialEfficacy outcome
In women with endometriosis, added hPTH prevented total body bone loss during nafarelin therapy.
In plain wordsIn women with endometriosis, added hPTH prevented whole-body bone loss compared with nafarelin alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal body bone loss prevention
Study
n = 43
Comparator
Nafarelin alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
BMD change from baseline
2%
Total body, nafarelin alone (comparator arm), lower than baseline at 12 months
Source sentences
Summary
In contrast, coadministration of hPTH-(1-34) increased BMD of the anterior-posterior spine by 2.1% (1.1%) (P=.09) and lateral spine by 7.5% (1.9%) (P=.002) and prevented bone loss from the femoral neck, trochanter, and total body, despite severe estrogen deficiency.
5 context sentences(design, population, supporting numbers)
Summary · context
In the women who received nafarelin alone, the mean (SEM) BMDs of the anterior-posterior spine, lateral spine, femoral neck, trochanter, and total body were 4.9% (0.6%) (P<.001), 4.9% (0.8%) (P<.001), 4.7% (1.1%) (P<.001), 4.3% (0.9%) (P<.001), and 2.0% (0.6%) (P= .003) lower than at baseline after…
Summary · context
Randomized controlled trial.
Summary · context
Nafarelin alone (200 microg intranasally twice daily) or nafarelin plus human parathyroid hormone-(1-34) (hPTH-[1-34]) (40 microg subcutaneously daily).
Summary · context
The primary end points were bone mineral density (BMD) of the anterior-posterior and lateral spine, femoral neck, trochanter, radial shaft, and total body at 12 months of treatment.
Summary · context
Forty-three women between the ages of 21 and 45 years with symptomatic endometriosis.
Report a problemFND-0975785405
04HumanRandomized controlled trialEfficacy outcome
In women receiving nafarelin, added hPTH produced a nonsignificant increase in anterior-posterior spine BMD from baseline.
In plain wordsIn women receiving nafarelin, added hPTH did not significantly change front-view spine bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeAnterior-posterior spine BMD
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
BMD change
2.1%
hPTH plus nafarelin
P
0.09
change from baseline
Source sentences
Summary
In contrast, coadministration of hPTH-(1-34) increased BMD of the anterior-posterior spine by 2.1% (1.1%) (P=.09) and lateral spine by 7.5% (1.9%) (P=.002) and prevented bone loss from the femoral neck, trochanter, and total body, despite severe estrogen deficiency.
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trial.
Summary · context
Forty-three women between the ages of 21 and 45 years with symptomatic endometriosis.
Summary · context
Nafarelin alone (200 microg intranasally twice daily) or nafarelin plus human parathyroid hormone-(1-34) (hPTH-[1-34]) (40 microg subcutaneously daily).
Report a problemFND-0975785401
05HumanRandomized controlled trialEfficacy outcome
In women receiving nafarelin, added hPTH increased lateral spine BMD from baseline.
In plain wordsIn women receiving nafarelin, added hPTH increased side-view spine bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLateral spine BMD
Study
n: not reported in source
Comparator
Baseline
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
BMD change
7.5%
hPTH plus nafarelin
Source sentences
Summary
In contrast, coadministration of hPTH-(1-34) increased BMD of the anterior-posterior spine by 2.1% (1.1%) (P=.09) and lateral spine by 7.5% (1.9%) (P=.002) and prevented bone loss from the femoral neck, trochanter, and total body, despite severe estrogen deficiency.
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trial.
Summary · context
Forty-three women between the ages of 21 and 45 years with symptomatic endometriosis.
Summary · context
Nafarelin alone (200 microg intranasally twice daily) or nafarelin plus human parathyroid hormone-(1-34) (hPTH-[1-34]) (40 microg subcutaneously daily).
Report a problemFND-0975785402
06HumanRandomized controlled trialEfficacy outcome
In women receiving nafarelin plus hPTH, bone-specific alkaline phosphatase increased early and then declined.
In plain wordsIn women receiving nafarelin plus hPTH, a bone formation marker increased from baseline and then declined.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedBone-specific alkaline phosphatase
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Fold increase
2 to 3 fold
nafarelin plus hPTH-(1-34), first 6 to 9 months; range reported jointly for the four bone markers
Source sentences
Summary
Serum bone-specific alkaline phosphatase and osteocalcin concentrations and urinary excretion of hydroxyproline and deoxypyridinoline increased 2-fold to 3-fold during the first 6 to 9 months of therapy in the women who received nafarelin plus hPTH-(1-34) and then declined.
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trial.
Summary · context
Forty-three women between the ages of 21 and 45 years with symptomatic endometriosis.
Summary · context
Nafarelin alone (200 microg intranasally twice daily) or nafarelin plus human parathyroid hormone-(1-34) (hPTH-[1-34]) (40 microg subcutaneously daily).
Report a problemFND-0975785407
07HumanRandomized controlled trialEfficacy outcome
In women receiving nafarelin plus hPTH, serum osteocalcin increased early and then declined.
In plain wordsIn women receiving nafarelin plus hPTH, blood osteocalcin increased from baseline and then declined.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedOsteocalcin
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Fold increase
2 to 3 fold
nafarelin plus hPTH-(1-34), first 6 to 9 months; range reported jointly for the four bone markers
Source sentences
Summary
Serum bone-specific alkaline phosphatase and osteocalcin concentrations and urinary excretion of hydroxyproline and deoxypyridinoline increased 2-fold to 3-fold during the first 6 to 9 months of therapy in the women who received nafarelin plus hPTH-(1-34) and then declined.
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trial.
Summary · context
Forty-three women between the ages of 21 and 45 years with symptomatic endometriosis.
Summary · context
Nafarelin alone (200 microg intranasally twice daily) or nafarelin plus human parathyroid hormone-(1-34) (hPTH-[1-34]) (40 microg subcutaneously daily).
Report a problemFND-0975785408
08HumanRandomized controlled trialEfficacy outcome
In women receiving nafarelin plus hPTH, urinary hydroxyproline increased early and then declined.
In plain wordsIn women receiving nafarelin plus hPTH, urine hydroxyproline increased from baseline and then declined.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedUrinary hydroxyproline
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Fold increase
2 to 3 fold
nafarelin plus hPTH-(1-34), first 6 to 9 months; range reported jointly for the four bone markers
Source sentences
Summary
Serum bone-specific alkaline phosphatase and osteocalcin concentrations and urinary excretion of hydroxyproline and deoxypyridinoline increased 2-fold to 3-fold during the first 6 to 9 months of therapy in the women who received nafarelin plus hPTH-(1-34) and then declined.
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trial.
Summary · context
Forty-three women between the ages of 21 and 45 years with symptomatic endometriosis.
Summary · context
Nafarelin alone (200 microg intranasally twice daily) or nafarelin plus human parathyroid hormone-(1-34) (hPTH-[1-34]) (40 microg subcutaneously daily).
Report a problemFND-0975785409
09HumanRandomized controlled trialEfficacy outcome
In women receiving nafarelin plus hPTH, urinary deoxypyridinoline increased early and then declined.
In plain wordsIn women receiving nafarelin plus hPTH, urine deoxypyridinoline increased from baseline and then declined.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedUrinary deoxypyridinoline
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Fold increase
2 to 3 fold
nafarelin plus hPTH-(1-34), first 6 to 9 months; range reported jointly for the four bone markers
Source sentences
Summary
Serum bone-specific alkaline phosphatase and osteocalcin concentrations and urinary excretion of hydroxyproline and deoxypyridinoline increased 2-fold to 3-fold during the first 6 to 9 months of therapy in the women who received nafarelin plus hPTH-(1-34) and then declined.
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trial.
Summary · context
Forty-three women between the ages of 21 and 45 years with symptomatic endometriosis.
Summary · context
Nafarelin alone (200 microg intranasally twice daily) or nafarelin plus human parathyroid hormone-(1-34) (hPTH-[1-34]) (40 microg subcutaneously daily).
Report a problemFND-0975785410

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

10HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In women with endometriosis, radial shaft BMD did not change significantly in either randomized group.
In plain wordsIn women with endometriosis, forearm bone density did not change significantly in either group, including nafarelin alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeRadial shaft BMD
Study
n = 43
Comparator
Baseline
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Radial shaft BMD did not change significantly in either group.
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trial.
Summary · context
Forty-three women between the ages of 21 and 45 years with symptomatic endometriosis.
Summary · context
Nafarelin alone (200 microg intranasally twice daily) or nafarelin plus human parathyroid hormone-(1-34) (hPTH-[1-34]) (40 microg subcutaneously daily).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-0975785406
11HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In women receiving nafarelin plus hPTH, urinary deoxypyridinolone changes predicted spinal BMD changes.
In plain wordsIn treated women, changes in a urine bone marker were linked to changes in spine bone density.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseDeoxypyridinolone change predicts spinal BMD change
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
Correlation
0.85 r
deoxypyridinolone and spinal BMD changes
Source sentences
Summary
Changes in urinary deoxypyridinolone excretion were strongly predictive (r= 0.85) of changes in spinal BMD in the women who received nafarelin plus hPTH-(1-34).
3 context sentences(design, population, supporting numbers)
Summary · context
Randomized controlled trial.
Summary · context
Forty-three women between the ages of 21 and 45 years with symptomatic endometriosis.
Summary · context
Nafarelin alone (200 microg intranasally twice daily) or nafarelin plus human parathyroid hormone-(1-34) (hPTH-[1-34]) (40 microg subcutaneously daily).
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-0975785411

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.